ImmuLogic Pharmaceutical Corp.'s Phase III study of its Allervax Ragweed peptide revealed a dosing regimen good enough to warrant continued development, but the outcome wasn't sufficient to support the company's hopes for a PLA submission to the FDA for marketing approval.

One of the two dosage groups in the trial achieved statistical significance versus placebo. But the other, which had worked in an earlier study and would have provided the basis for PLA discussions with the FDA, didn't reach significance.